US Pharma MarketingThe post Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test appeared first on Medical Device Network.
Vivos to buy 50% stake in SOD Sciences' pseudohypoxia test
Vivos Therapeutics has entered into a definitive agreement for an 11% fully diluted equity interest in SOD Sciences along with a 50% undivided co-ownership stake in its pseudohypoxia early-warning diagnostic test. Vivos will receive 50% of the contribution margin from sales of the diagnostic test across all channels. The pseudohypoxia test combines SOD’s ReBalU genotype and biomarker panel with oxygen desaturation measurements to detect chronic diseases. Credit: angellodeco/Shutterstock.com. Vivos Therapeutics has entered into a definitive agreement for an 11% fully diluted equity interest in SOD Sciences along with a 50% undivided co-ownership stake in its pseudohypoxia early-warning diagnostic test. Under…
Vivos Therapeutics has entered into a definitive agreement for an 11% fully diluted equity interest in SOD Sciences along with a 50% undivided co-ownership stake in its pseudohypoxia early-warning diagnostic test.
Source: Medical Device Network